Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02622334 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A Phase 1 study of Glaucoma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT02622334 is a Phase 1 study of Glaucoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 45 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT02622334, a Phase 1 study of Glaucoma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Latanoprost
- DRUG RO5093151
Study Locations (7)
California
- Sall Research Medical Center - Artesia
Colorado
- Rocky Mountain Lions Eye Inst - Aurora
Georgia
- Eye Care Centers Management, Inc. (Clayton Eye Center) - Morrow
New York
- New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute - New York
North Carolina
- Cornerstone Eye Care, Div of Cornerstone Health Care - High Point
West Virginia
- West Virginia University Eye Institute - Morgantown
Other
- Singapore National Eye Centre; Glaucoma Department - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-12-29 |
| Est. Completion | 2016-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02622334
The ClinicalTrials.gov registry entry for NCT02622334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02622334 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT02622334 about?
NCT02622334 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).". The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
What is the current status of trial NCT02622334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2015-12-29. Estimated completion is 2016-07-28.
What conditions does trial NCT02622334 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT02622334?
The interventions under investigation include: Placebo (DRUG), Latanoprost (DRUG), RO5093151 (DRUG).
Who is sponsoring clinical trial NCT02622334?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02622334 being conducted?
This trial has 7 study locations across California, Colorado, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.